(Q35093095)

6 August 2017

1 reference

title

Early prostate cancer: clinical decision-making (English)

1 reference

6 August 2017

1 reference

1 reference

Ashesh B Jani

1

1 reference

6 August 2017

Samuel Hellman

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

361

1 reference

6 August 2017

issue

9362

1 reference

6 August 2017

page(s)

1045-1053

1 reference

Impact of screening on incidence and mortality of prostate cancer in the United States

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Cancer burden in the year 2000. The global picture

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Detection of extracapsular extension of prostate cancer: role of fat suppression endorectal MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Current status of minimally invasive treatment options for localized prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

5-Year Tumor Recurrence Rates After Anatomical Radical Retropubic Prostatectomy For Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Failure patterns and hazard rates for failure suggest the cure of prostate cancer by external beam radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Palladium-103 brachytherapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Natural history of localised prostatic cancer managed by conservative therapy alone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Natural course of clinically localized prostate adenocarcinoma in men less than 70 years old.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Long-term impact of conservative management on localized prostate cancer. A twenty-year experience in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Results of conservative management of clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Surveillance is not a viable and appropriate treatment option in the management of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Prostate cancer mortality in northern Sweden, with special reference to tumor grade and patient age

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Radical retropubic prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Laparoscopic radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Laparoscopic radical prostatectomy: the Montsouris experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Radical prostatectomy and cystoprostatectomy with preservation of potency. Results using a new nerve-sparing technique

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

The role of radical prostatectomy in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Results of radical prostatectomy in men with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Indications and contraindications for nerve-sparing radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Prostate cancer: natural history and surgical treatment of localised disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Radical prostatectomy: time trends, morbidity and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Prognostic significance of positive surgical margins in radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Continence, potency and morbidity after radical perineal prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Variations in morbidity after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Patient-Reported Impotence and Incontinence After Nerve-Sparing Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

A RANDOMIZED PHASE 3 STUDY OF INTRAOPERATIVE CAVERNOUS NERVE STIMULATION WITH PENILE TUMESCENCE MONITORING TO IMPROVE NERVE SPARING DURING RADICAL PROSTATECTOMY

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Prevention and management of erectile dysfunction following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Management of erectile dysfunction secondary to treatment for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Risk of positive margins and biochemical recurrence in relation to nerve-sparing radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Definitive radiation therapy of carcinoma of the prostate. A report on 15 years of experience. 1973.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Control of prostate cancer with radiotherapy: long-term results.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Correlation of radiotherapeutic parameters and treatment related morbidity--analysis of RTOG Study 77-06

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Sexual (dys)function after radiotherapy for prostate cancer: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: a randomized, double-blind, placebo-controlled, cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Analysis of prostate and seminal vesicle motion: implications for treatment planning

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Prostate motion during standard radiotherapy as assessed by fiducial markers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Review article: current therapeutic options for radiation proctopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Retropubic Implantation of Iodine 125 in the Treatment of Prostatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Prostate brachytherapy: importance of technique

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Rectal function following prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Potency after permanent prostate brachytherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

The dosimetry of prostate brachytherapy-induced urethral strictures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Use of TRUS to predict pubic arch interference of prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Neoadjuvant and adjuvant hormone therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Assessment of the feasibility and impact of shared decision making in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

An evidence-based analysis of the management of localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Have complication rates decreased after treatment for localized prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Quality of life aspects of treatment options for localized and locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Management of locally advanced prostate cancer. 1. Staging, natural history, and results of radical surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

Treatment of locally advanced prostate cancer: is chemotherapy the next step?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912833-4

7 January 2021

10.1016/S0140-6736(03)12833-4

Identifiers

DOI

1 reference

6 August 2017

1 reference